DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is placed.
Limited alternatives and high unmet needs have made global cancer market to rise unexpectedly and is presumed to reach around $ 100-110 billion by 2020. Recently companies have come up with new targeted therapies involving Immunotherapy. It is a major technological breakthrough in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease which are expected to deliver improved results in terms of safety and efficacy.
The current Oncology market is steered by companies such as Roche for Avastin, Herceptin & Rituxan, Novartis for Gleevac/Glivec and Celgene for Revlimid.
DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA). DelveInsight’s Reports on gene therapy, PD-1/PDL-1, Antibody-Drug Conjugate (ADC) & CAR-T provides assessment over advancement in technologies, market trend, partnering & licensing opportunities, pipeline scenario and competitive landscape. In addition, the Oncology Reports will help to identify the key players of market and the potential market movers and barriers. After getting great response and feedback now we are planning to launch reports on Stem Cell Oncology, Bruton’s Tyrosine Kinase (BTK) Inhibitors, TIM3, OX40, and LAG3.
DelveInsight’s Oncology reports help companies in understanding Oncology market dynamics and therefore giving opportunities for strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition, reports will assuage companies to detect specific tumors, determine genetic predisposition and biological response to cancer therapy.
